Abstract
Background: The interest in cannabidiol (CBD) for treatment of epilepsy has been increasing over the last years. However, practitioner's attitudes concerning the use of CBD for epilepsy treatment appears to be divided and data about its clinical use in daily practice are not available.Objective: To improve the knowledge about the current use of CBD amongst European practitioners treating children and adolescents for epilepsy.Methods: Cross-sectional survey using an open-access online questionnaire for physicians treating children or adolescents for epilepsy within eight European countries from December 2017 to March 2018.Results: One-hundred fifty-five physicians participated in the survey. CBD is increasingly used by 45% (69/155) of participants, treating a mean (range) number of 3 (1–35) with CBD. Only 48% of the participants prescribing CBD are exclusively using purified CBD to treat children and adolescents with epilepsy, the remainder also applies preparations containing delta9-tetrahydrocannabinol (THC). Reported daily CBD doses range from < 10 to 50 mg/kg body weight. Management of CBD therapy in regard of monitoring side effects and adjusting concomitant therapy differs widely amongst participants. Their primary objective for commencing CBD is improving patient's quality of life. Participants frequently receive inquiries about CBD treatment but only 40% may actively suggest CBD as a treatment option. Of the 85 participants currently not using CBD for epilepsy treatment, 70% would consider using CBD if available in their country of practice or given the opportunity to become familiar with this treatment option.Conclusions: CBD is increasingly used by participating physicians but individual experience remains limited. There are very diverse opinions about the use of CBD to treat epilepsy in children and adolescents and widely differing views on how to manage the CBD treatment.
Highlights
Cannabidiol (CBD), an active cannabinoid without psychotropic effects and abuse liability, has recently gained interest as a treatment option for intractable epilepsy [1]
The clinical evidence to support the use of CBD is limited to retrospective case series [5,6,7], open label studies [8, 9] and two randomized controlled trials in children suffering from Dravet and Lennox-Gastaut syndrome [10, 11]
Practitioner’s attitudes concerning the use of medical cannabis in general and CBD for treatment of epilepsy in particular appears to be divided [13, 14] and data about its clinical use in daily practice are not available. The aim of this cross-sectional survey was to improve the knowledge about the current use of CBD amongst European practitioners treating children and adolescents for epilepsy
Summary
Cannabidiol (CBD), an active cannabinoid without psychotropic effects and abuse liability, has recently gained interest as a treatment option for intractable epilepsy [1]. Practitioner’s attitudes concerning the use of medical cannabis in general and CBD for treatment of epilepsy in particular appears to be divided [13, 14] and data about its clinical use in daily practice are not available. The aim of this cross-sectional survey was to improve the knowledge about the current use of CBD amongst European practitioners treating children and adolescents for epilepsy. Practitioner’s attitudes concerning the use of CBD for epilepsy treatment appears to be divided and data about its clinical use in daily practice are not available
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
